Abstract: The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.

Abstract: The present disclosure relates to compositions and methods for enhancing infiltration of lymphocytes into tumor tissue, enhancing anti-tumor lymphocyte activities in tumor microenvionment (TME), inhibiting regulatory lymphocyte (e.g., B and T cells) activities in TME, and/or long term benefit of cell therapies. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds FCR1, MSLN, GPC-3, ALPP, CD70, CLDN6, ROR1, CD205, ACPP, ADAM12, or CLDN18.2.

Abstract: The present embodiments relate to pathogen clearance. Subject matter of the present embodiments are computer-implemented methods, computer systems and computer-readable storage media for predicting the performance of pathogen clearance processes.

Abstract: This disclosure relates to methods for use in inactivating viruses. The methods of inactivating viruses with N-methylglucamides is applicable to the purification process of biologically-active drugs such as protein subunits, proteins (enzymes, factors, etc.), recombinant proteins, antibodies, vaccine or gene therapeutic products. The detergents used in this method are based on multiple N-methylglucamide homologs, consisting of a hydrophilic glucose moiety and hydrophobic fatty acid tail, linked by an amide bond. Additionally, these sugar-based detergents are nonionic by nature, which do not disrupt the drug protein, plasma biologics, non-enveloped viral vaccine or adeno associated viral particles.

Abstract: This disclosure relates to methods for use in inactivating viruses. The methods of inactivating viruses with N-methylglucamides is applicable to the purification process of biologically-active drugs such as protein subunits, proteins (enzymes, factors, etc.), recombinant proteins, antibodies, vaccine or gene therapeutic products. The detergents used in this method are based on multiple N-methylglucamide homologs, consisting of a hydrophilic glucose moiety and hydrophobic fatty acid tail, linked by an amide bond. Additionally, these sugar-based detergents are nonionic by nature, which do not disrupt the drug protein, plasma biologies, non-enveloped viral vaccine or adeno associated viral particles.

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Abstract: The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.

Abstract: The present disclosure relates to compositions and methods of treating a subject having digestive tract cancer, the method comprising: administering an effective amount of a composition to the subject, the composition comprising a first population of cells comprising a first CAR binding a first antigen, and a second population of cells comprising a second CAR binding GCC, wherein the first antigen comprises a cell surface molecule of a white blood cell (WBC).

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Abstract: A first-layer insulating film having a barrier property against a determined element contained in a ferroelectric capacitor as well as an oxygen permeability, a hydrogen permeability, and a water permeability is formed over a surface of the ferroelectric capacitor formed over a substrate. After that, heat treatment is performed in an oxidizing atmosphere. After the heat treatment, a second insulating film having a hydrogen permeability and a water permeability lower than those of the first-layer insulating film respectively is formed over a surface of the first-layer insulating film in a non-reducing atmosphere. A third-layer insulating film is formed over a surface of the second-layer insulating film. By doing so, degradation of a ferroelectric film under and after the formation of a semiconductor device having the ferroelectric capacitor is suppressed and deterioration in the characteristics of the ferroelectric capacitor is suppressed.

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Abstract: The present disclosure describes a method of producing T cells exhibiting an enhanced memory T cell phenotype, the method comprising: modulating a population of T cells to enhance the expression and/or function of high mobility group protein Y (HMGY). In embodiments, the method may include introducing a polynucleotide encoding HMGY into a population of T cells, wherein expression of HMGY is higher in the population of T cells as compared to a population of T cells that are not introduced with the polynucleotide, and the memory T cell phenotype of the population of T cells is enhanced as compared to T cells that are not introduced with the polynucleotide. In embodiments, the method can also include introducing a polynucleotide encoding one or more genes associated with HMGY, for example, upstream or downstream of the signaling pathway associated with HMGY and/or a transcription factor associated with HMGY.

Abstract: The embodiments provide a modified filter membrane for separating a crude solution of a biological product and a viral contaminant. The filter membrane has a cellulosed based porous surface, and at least one divalent metal ion bound to the cellulose based porous surface of the filter membrane to form a modified filter membrane cellulose based porous surface, wherein the modified cellulose based porous surface separates the crude solution by retaining a viral contaminant greater than 15 nm in diameter while allowing a biological product smaller than 15 nm in diameter to pass through.

Abstract: This disclosure relates to methods for use in inactivating viruses. The methods of inactivating viruses with N-methylglucamides is applicable to the purification process of biologically-active drugs such as protein subunits, proteins (enzymes, factors, etc.), recombinant proteins, antibodies, vaccine or gene therapeutic products. The detergents used in this method are based on multiple N-methylglucamide homologs, consisting of a hydrophilic glucose moiety and hydrophobic fatty acid tail, linked by an amide bond. Additionally, these sugar-based detergents are nonionic by nature, which do not disrupt the drug protein, plasma biologies, non-enveloped viral vaccine or adeno associated viral particles.

Abstract: A first-layer insulating film having a barrier property against a determined element contained in a ferroelectric capacitor as well as an oxygen permeability, a hydrogen permeability, and a water permeability is formed over a surface of the ferroelectric capacitor formed over a substrate. After that, heat treatment is performed in an oxidizing atmosphere. After the heat treatment, a second insulating film having a hydrogen permeability and a water permeability lower than those of the first-layer insulating film respectively is formed over a surface of the first-layer insulating film in a non-reducing atmosphere. A third-layer insulating film is formed over a surface of the second-layer insulating film. By doing so, degradation of a ferroelectric film under and after the formation of a semiconductor device having the ferroelectric capacitor is suppressed and deterioration in the characteristics of the ferroelectric capacitor is suppressed.

Abstract: A system for handling data skew includes a cluster of computing nodes and a processor. The cluster includes one or more first nodes, each of which has a storage, and one or more second nodes, each of which has a storage. The storage of the respective second nodes has a higher access speed than the storage of the respective first nodes. The processor is configured to split input data into partitions of the input data, to detect if any of the partitions has data skew, and to assign ones of the partitions, which are detected as having no data skew, to the first nodes, and ones of the partitions, which are detected as having the data skew, to the second nodes, for parallel processing.

Abstract: A system for handling data skew includes a cluster of computing nodes and a processor. The cluster includes one or more first nodes, each of which has a storage, and one or more second nodes, each of which has a storage. The storage of the respective second nodes has a higher access speed than the storage of the respective first nodes. The processor is configured to split input data into partitions of the input data, to detect if any of the partitions has data skew, and to assign ones of the partitions, which are detected as having no data skew, to the first nodes, and ones of the partitions, which are detected as having the data skew, to the second nodes, for parallel processing.

Abstract: A coordinated parking-monitoring system comprises a plurality of camera-based parking-monitoring devices. Each camera in the coordinated parking-monitoring system can effectively monitor more parking areas than a single camera-based parking-monitoring device.

Abstract: A coordinated parking-monitoring system comprises a plurality of camera-based parking-monitoring devices. Each camera in the coordinated parking-monitoring system can effectively monitor more parking areas than a single camera-based parking-monitoring device.